ACASA-TAVIHot Line 7Structural Heart
Antithrombotic Therapy After Transcatheter Aortic Valve Implantation
Antithrombotic therapy after transcatheter aortic valve implantation
Presenting authorØyvind H. LieInterventional / Structural Cardiology · Oslo University HospitalØyvind H. Lie, MD, PhD, is an interventional cardiologist at the Department of Cardiology, Oslo University Hospital, Rikshospitalet. He is affiliated with the ProCardio Center for Innovation and University of Oslo, with research on cardiomyopathy and arrhythmias.
Overview
Clinicians should await pending TAVI antithrombotic trial results before altering regimens; leaves open optimal strategy.
Key result
Antithrombotic therapy after transcatheter aortic valve implantation is being evaluated in a late-breaking trial with results currently pending.
Discussion
Expert reaction lands here the moment ACASA-TAVI reports.
Key Points
- Post-procedural antithrombotic therapy aims to prevent thromboembolic events following transcatheter aortic valve implantation while minimizing major bleeding.
- Clinical trial presentation outlines management strategies for antithrombotic therapy after transcatheter aortic valve implantation at ESC Congress 2026.
- Highlights evolving clinical strategies for prosthetic heart valve management—full outcome analysis remains pending upcoming late-breaking presentation.
Main Result
Absolute Event Rate: 0% vs 0%